Project update – Progress on pipeline assets NXP002 and NXP004

1st June 2021

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, post-fund raising, it has started the planned studies on its pipeline assets NXP002 (new form of tranilast) and NXP004 (undisclosed oncology drug).

Download News

Back to all News